Jeffrey Peppercorn

Jeffrey Peppercorn MD

@ethicsdoctorp.bsky.social

710 followers 110 following 21 posts

Oncologist and Bioethicist with interest in health policy and rock n roll. Editor-in-Chief JCO Oncology Practice.

Videos

Economics 37%

Biology 32%

Posts Replies Media Videos

Reposted by Jeffrey Peppercorn

Julie Gralow @jrgralow.bsky.social · Sep 13

Terrific (&entertaining) piece by @jco-asco.bsky.social OP editor @ethicsdoctorp.bsky.social on what he thinks AI could do to transform oncology practice by 2035.

OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice ascopubs.org/doi/full/10....

OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice

ascopubs.org

Reposted by Jeffrey Peppercorn

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · Jun 14

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice

PURPOSEImmune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyro...

ascopubs.org

Reposted by Jeffrey Peppercorn

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · Jun 3

Another great #ASCO25

Also wonderful to see my amazing JCO Oncology Practice colleagues! 📝

Loved Dr. DeMichele’s discussion of SERENA-6 and the incredible CHALLENGE trial data for exercise in colon cancer survivors. 🏃‍♂️

And a chance to hang out for a few hours with my daughter! 🥰

Reposted by Jeffrey Peppercorn

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · May 15

Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of JCO Oncology Practice | JCO Oncology Practice ascopubs.org/doi/10.1200/...
A fun collaboration and nostolgic review by those fortunate to serve as Editor-in-Chief over the past 20 years. 🥳

Reposted by Jeffrey Peppercorn

Robert S Miller MD @rsm2800.bsky.social · May 14

Congrats to ASCO's journal JCO Oncology Practice on your 20-yr anniversary! JCO OP is the unquestioned and authoritative leader on issues of cancer care policy, delivery, & quality ascopubs.org/doi/full/10....

Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of JCO Oncology Practice | JCO Oncology Practice

ascopubs.org

Reposted by Jeffrey Peppercorn

Ryan Nipp, MD, MPH, MBA, FASCO @ryannipp.bsky.social · May 13

Glory Days: Celebrating Two Decades of Advances in #Cancer Care on the 20th Anniversary of JCO Oncology Practice.

ascopubs.org/doi/full/10....

@ascocancer.bsky.social
#CancerCare #FinancialToxicity #CancerResearch
@ethicsdoctorp.bsky.social @fumikochino.bsky.social @jameabraham.bsky.social

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · May 13

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

ascopubs.org

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · May 5

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice

PURPOSEClear prognostic communication is associated with improvements in quality of life and suffering for children with advanced illness. Yet recent evidence demonstrates that pediatric oncologists o...

ascopubs.org

Jeffrey Peppercorn MD @ethicsdoctorp.bsky.social · Apr 28

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan | JCO Oncology Practice ascopubs.org/doi/10.1200/...

PURPOSEMedicare Part D beneficiaries who do not qualify for low-income subsidies face high out-of-pocket (OOP) costs for brand-name specialty oral anticancer medications (SOAMs). We calculated how OOP...

ascopubs.org

Reposted by Jeffrey Peppercorn

Emilie Gunn @emiliemgunn.bsky.social · Apr 28

📣 Have something to report on an ongoing clinical trial? #JCOOA now accepting Trials in Progress articles! Read the first one here:

SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low–Tumor Burden Follicular Lymphoma ascopubs.org/doi/10.1200/...

SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma | JCO Oncology Advances

ascopubs.org

Reposted by Jeffrey Peppercorn

Ryan Nipp, MD, MPH, MBA, FASCO @ryannipp.bsky.social · Apr 22

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy.

ascopubs.org/doi/10.1200/...

@ascopost.bsky.social
@pallonccop.bsky.social
#Immunotherapy #CancerResearch
@ethicsdoctorp.bsky.social

Light upyour news

Sign in to Lightnews

Sign up to start reading

Connect Bluesky

Connect with Bluesky

Light up
your news